Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M07D1 vs DS-8201 in HR-Positive, HER2-Low Recurrent/Metastatic Breast Cancer
NCT07678957Phase 2Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Aug 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of BL-M07D1 in breast cancer (2 arms), sponsored by Biokin Pharmaceutical. Primary endpoint: Progression-free survival at 24 months. Started Aug 2026; status: recruiting.
02
Drugs
BL-M07D1
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07678957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07678957.